摘要
血脂异常是心血管病的主要危险因素,尤其是低密度脂蛋白胆固醇(LDLC)升高显著增加动脉粥样硬化性心血管疾病(ASCVD)发病率。他汀类药物已被证实可以有效降低血清LDLC,进而减少ASCVD发生风险。但是在他汀类药物的临床应用过程中,越来越多的研究显示他汀类药物存在耐药性,即药物抵抗。研究表明,他汀类药物抵抗主要受药物在体内的吸收、转运、代谢以及药物作用本身的影响。深入研究他汀类药物抵抗可为进一步揭示他汀类药物作用机制提供理论依据,并有望为研发新的降脂药物提供靶点。
Dyslipidemia is a major risk factor for cardiovascular disease, especially elevated low density lipoprotein cholesterol(LDLC) significantly increases the incidence of atherosclerotic cardiovascular disease(ASCVD). Statins have shown to be effective in reducing serum LDLC, thereby reducing the risk of ASCVD. However, in the course of clinical application of statins, more and more studies show that statins have drug resistance. Studies have shown that statin resistance is mainly affected by drug absorption, transport, metabolism and drug action itself. Intensive study of statin resistance can provide theoretical basis for further revealing the action mechanism of statins, and hopefully provide a target for the development of new lipid-lowering drugs.
引文
[1] 国家卫生和计划生育委员会疾病预防控制局.中国居民营养与慢性病状况报告(2015年)发布[J].上海医药,2015,36(13):79.
[2] Moran A,Gu D,Zhao D,et al.Future cardiovascular disease in china:markov model and risk factor scenario projections from the coronary heart disease policy model-china[J].Circ Cardiovasc Qual Outcomes,2010,3(3):243-252.
[3] 胡大一.降低密度脂蛋白胆固醇是硬道理[J].中华心血管病杂志,2015,43(1):3-4.
[4] Cholesterol Treatment Trialists’ (CTT) Collaboration,Baigent C,Blackwell L,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomized trials[J] .Lancet,2010,376(9753):1670-1681.
[5] 朱小莉,周云,孙晓靖.冠心病危险因素分析及其与冠状动脉狭窄程度的关系[J].中国循证心血管医学杂志,2017,9(12):1513-1515.
[6] 诸仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[7] Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS Guidelines for the management of dyslipidaemias[J].Kardiol Pol,2016,74(11):1234-1318.
[8] Jellinger PS,Handelsman Y,Rosenblit PD,et al.American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease[J].Endocr Pract,23(Suppl 2):1-87.
[9] Goldstein JL,Brown MS.A century of cholesterol and coronaries:from plaques to genes to statins[J].Cell,2015,161(1):161-172.
[10] Tiwari V,Khokhar M.Mechanism of action of anti-hypercholesterolemia drugs and their resistance[J].Eur J Pharmacol,2014,741:156-170.
[11] Reiner Z.Resistance and intolerance to statins[J].Nutr Metab Cardiovasc Dis,2014,24(10):1057-1066.
[12] Zhao SP,Yu BL,Peng DQ,et al.The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China:Results of the CHILLAS trial[J].Atherosclerosis,2014,233(2):707-712.
[13] 刘劲松,曾小莉,李娟.他汀类药物治疗心血管获益与糖尿病风险[J].中国循证心血管医学杂志,2016,8(12):1534-1536.
[14] Chasman DI,Posada D,Subrahmanyan L,et al.Pharmacogenetic study of statin therapy and cholesterol reduction[J].JAMA,2004,291(23):2821-2827.
[15] Thompson JF,Man M,Johnson KJ,et al.An association study of 43 SNPs in 16 candidate genes with atorvastatin response[J].Pharmacogenomics J,2005,5(6):352-358.
[16] Polisecki E,Muallem H,Maeda N,et al.Genetic variation at the LDL receptor and HMG-CoA reductase gene loci,lipid levels,statin response,and cardiovascular disease incidence in PROSPER[J].Atherosclerosis,2008,200(1):109-114.
[17] Chasman DI,Giulianini F,MacFadyen J,et al.Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction:the Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial[J].Circ Cardiovasc Genet,2012,5(2):257-264.
[18] Thompson JF,Hyde CL,Wood LS,et al.Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort[J].Circ Cardiovasc Genet,2009,2(2):173-181.
[19] Reiner ?,Tedeschi-Reiner E.Prevalence and types of persistent dyslipidemia in patients treated with statins[J].Croat Med J,2013,54(4):339-345.
[20] Leusink M,Onland-Moret NC,de Bakker PI,et al.Seventeen years of statin pharmacogenetics:a systematic review[J].Pharmacogenomics,2016,17(2):163-180.
[21] Polisecki E,Peter I,Simon JS,et al.Genetic variation at the NPC1L1 gene locus,plasma lipoproteins,and heart disease risk in the elderly[J].J Lipid Res,2010,51(5):1201-1207.
[22] Hubacek JA,Vrablik M.Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events[J].Drug Metabol Drug Interact,2011,26(1):13-20.
[23] Donnelly LA,van Zuydam NR,Zhou K,et al.Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment[J].Pharmacogenet Genomics,2013,23(10):518-525.
[24] Keyser CE,Eijgelsheim M,Hofman A,et al.Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy:the Rotterdam Study[J].Pharmacogenomics J,2011,11(1):72-80.
[25] Rebecchi IM,Rodrigues AC,Arazi SS,et al.ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment[J].Biochem Pharmacol,2009,77(1):66-75.
[26] Generaux GT,Bonomo FM,Johnson M,et al.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins[J].Xenobiotica,2011,41(8):639-651.
[27] Hu M,Lui SS,Tam LS,et al.The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin[J].J Lipid Res,2012,53(7):1384-1389.
[28] Krauss RM,Mangravite LM,Smith JD,et al.Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment[J].Circulation,2008,117(12):1537-1544.
[29] Dong B,Wu M,Li H,et al.Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2:mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters[J].J Lipid Res,2010,51(6):1486-1495.
[30] Kajinami K,Brousseau ME,Ordovas JM,et al.A promoter polymorphism in cholesterol 7 alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin[J].Atherosclerosis,2005,180(2):407-415.
[31] Medina MW,Theusch E,Naidoo D,et al.RHOA is a modulator of the cholesterol-lowering effects of statin[J].PLoS Genet,2012,8(11):e1003058.
[32] Maggo SD,Kennedy MA,Clark DW,et al.Clinical implications of pharmacogenetic variation on the effects of statins[J].Drug Saf,2011,34(1):1-19.
[33] Moon YA.The SCAP/SREBP pathway:A mediator of hepatic steatosis[J].Endocrinol Metab (Seoul),2017,32(1):6-10.
[34] Yu CY,Theusch E,Lo K,et al.HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism[J].Hum Mol Genet,2014,23(2):319-332.
[35] Bao H,Li F,Wang C,et al.Structural basis for the specific recognition of RhoA by the dual GTPase-activating protein ARAP3[J].J Biol Chem,2016,291(32):16709-16719.
[36] Hoshino D,Tomari T,Nagano M,et al.A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation,actin remodeling,and matrigel invasion[J].J Biol Chem,2009,284(40):27315-27326.
